BACKGROUND: We conducted a preliminary retrospective evaluation of the efficacy and @entity137 of proton-beam therapy (pbt) for stage iii @entity1149 . METHODS: Between January 2009 and August 2013, 27 @entity1 (26 @entity1 , 1 @entity1 ) with stage iii @entity1149 underwent pbt. The relative biologic effectiveness value of the proton beam was defined as 1.1. The beam energy and spread-out Bragg peak were fine-tuned such that the 90% isodose volume of the prescribed dose encompassed the planning target volume. Of the 27 @entity1 , 11 underwent neoadjuvant chemotherapy. Cumulative survival curves were calculated using the Kaplan-Meier method. Treatment @entity137 were evaluated using version 4 of the Common Terminology Criteria for Adverse Events. RESULTS: Median age of the @entity1 was 72 years (range: 57-91 years), and median follow-up was 15.4 months (range: 7.8-36.9 months). Clinical stage was iiia in 14 @entity1 (52%) and iiib in 13 (48%). The median dose of pbt was 77 GyE (range: 66-86.4 GyE). The overall survival rate in the cohort was 92.3% at 1 year and 51.1% at 2 years. Locoregional failure occurred in 7 @entity1 , and distant @entity3 , in 10. In 2 @entity1 , initial failure was both locoregional and distant. The 1-year and 2-year rates of local control were 68.1% and 36.4% respectively. The 1-year and 2-year rates of progression-free survival were 39.9% and 21.4% respectively. Two @entity1 experienced grade 3 @entity55 . CONCLUSIONS: For @entity1 with stage iii @entity1149 , pbt can be an effective and safe treatment option.

Preliminary results of proton-beam therapy for stage III XXXX .

@entity1 :: ('9606', 'Species') :: ['woman', 'patients', 'men'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['non-small-cell lung cancer'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small-cell lung cancer']
